Multinational Internet-based survey of patient preference for newer oral or injectable Type 2 diabetes medication | Zendy

Marco DiBonaventura | Zendy; Samuel C. Wagner | Zendy; Cynthia J. Girman | Zendy; Kimberly Kimberly Brodovicz | Zendy; Qiaoyi Zhang | Zendy; Ying Qiu | Zendy; P Sriram | Zendy; Larry Radican | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Multinational Internet-based survey of patient preference for newer oral or injectable Type 2 diabetes medication

Author(s) -

Marco DiBonaventura,

Samuel C. Wagner,

Cynthia J. Girman,

Kimberly Kimberly Brodovicz,

Qiaoyi Zhang,

Ying Qiu,

P Sriram,

Larry Radican

Publication year - 2010

Publication title -

patient preference and adherence

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.885

H-Index - 48

ISSN - 1177-889X

DOI - 10.2147/ppa.s14477

Subject(s) - sitagliptin , medicine , liraglutide , dipeptidyl peptidase 4 inhibitor , type 2 diabetes , sitagliptin phosphate , diabetes mellitus , type 2 diabetes mellitus , drug , pharmacology , endocrinology

The prevalence of Type 2 diabetes mellitus continues to rise. Although glucagon-like peptide-1 (GLP-1) analog and dipeptidyl peptidase-4 (DPP-4) inhibitor medications are effective, there are differences between these products, including method of administration (injectable versus oral). The objective of this study was to examine patient preferences (and predictors of preferences) for two different medication profiles, one similar to a GLP-1 analog (liraglutide) and another similar to a DPP-4 inhibitor (sitagliptin).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research